Recommended

Novartis selects fourth site for US radioligand manufacturing facility
EC approves Sanofi’s Teizeild for type 1 diabetes
WEBINAR | Reflections and future opportunities in pharmaceutical microbiology
WEBINAR | Harnessing AI for more efficient clinical trials | REGISTER TODAY
Increasing the effectiveness of pharma endotoxin testing | REGISTER NOW
WEBINAR | Practical considerations for aseptic gowning in contamination control strategies
Eur. Ph. publishes new general chapter on quality of data
AbbVie licenses novel bsAb from RemeGen for $5bn
EMA and FDA issue joint AI guidance
J&J’s Caplyta demonstrates phase III promise for major depressive disorder
Harnessing digital PCR for rapid sterility testing | WEBINAR
Realising autonomous pharmaceutical operations – register now
Explore the latest issue here
Complying with USP Chapters 41 and 1251 revisions for pharma quality control | WEBINAR
news

Eli Lilly selects new EVP of Global Quality

0
SHARES

The new Executive Vice President (EVP) has over “25 years of experience and a proven track record of leading strategic quality initiatives”, Eli Lilly and Company shared.

Eli Lilly quality

Credit: JHVEPhoto / Shutterstock.com

Eli Lilly and Company has announced its new Executive Vice President of Global Quality.

 

SECURE YOUR FREE SPOT

 


This webinar to explore rapid sterility testing methods that ensure fast, reliable product release, addressing critical challenges in timely delivery and safety.

Harnessing digital PCR for rapid sterility testing | 18 March 2026 | 3PM

What you’ll discover:

  • Rapid sterility testing methods that address the challenge of lengthy testing times, improving efficiency and ensuring timely product release
  • Insights into how digital PCR technology enhances testing accuracy and sensitivity, detecting contaminants quickly and reliably
  • Real-world case studies on rapid testing implementations in the field of cell and gene therapy

A Q&A session at the end of the webinar gives the audience a chance to ask questions, such as how to implement these technologies effectively.

Register now – it’s free

This news follows a statement by the firm at the start of this year declaring the retirement of its long-serving current EVP.

A new start at Eli Lilly

Melissa Seymour will begin her new role as EVP at Eli Lilly on 22 July 2024. As part of this position, she will also serve as a member of the company’s Executive Committee.

With more than 25 years of experience and a proven track record of leading strategic quality initiatives across product lifecycles, Melissa will further advance our culture of quality”

“As we expand global capacity to meet demand and support pipeline growth, we remain committed to ensuring our medicines are produced to the highest quality standards,” stated David Ricks, Lilly’s chair and CEO. “With more than 25 years of experience and a proven track record of leading strategic quality initiatives across product lifecycles, Melissa will further advance our culture of quality, which has been integral to our success in bringing innovative medicines to people around the world.”

Seymour commented on her appointment: “With the rapid expansion and promising pipeline at Lilly, maintaining high standards of quality is paramount and I am thrilled to play a role in shaping the company’s future.”

Previous roles

Seymour has held various senior leadership roles at global pharmaceutical companies. Currently, she is the Chief Quality Officer for Bristol Myers Squibb, Eli Lilly stated. Other companies include Biogen, Novo Nordisk and Glaxo Smith Kline. Her experience includes “development of quality compliance strategies, implemented quality processes and systems”, as well as developing talent.

According to Eli Lilly, Seymour has bachelor’s degrees in biological sciences and biochemistry from North Carolina State University. She also holds an executive MBA from Duke University and “several quality-related certifications from the American Society for Quality”. Furthermore, Seymour contributes on nonprofit boards, including the Parenteral Drug Association (PDA).

Investing for the future

Last month, Eli Lilly announced it planned to invest $5.3 billion to expand manufacturing capacity of active pharmaceutical ingredients (APIs) for Zepbound® (tirzepatide) injection and Mounjaro® (tirzepatide) injection at one of its US sites.

 
Share via
Share via